arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Anika Therapeutics, Inc.

ANIK
$19.31 ▼ -1.06 (-5.20%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Anika Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $257.4M
Dividend Yield —
Revenue Growth 15.6% ↗
Op. Margin 9.1% ↗
ROIC 2.1% ↗
FCF / Share $-0.16 ↗
Trailing P/E 77.2x
Price / Book 1.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$32.61M
↑ +15.6% —
Net Income Profit after all expenses
$-5.06M
↓ -3.8% —
Operating Margin Operating profit as % of sales
9.1%
↑ +148.9% 15th
FCF / Share Free cash flow per share
$-0.16
↑ +65.5% —
Long-Term Debt Long-term obligations
$25.00M
↓ -50.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
24
Returns
36
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 67 quarters